Data presented at the American Society of Clinical Oncology Annual Meeting in June 2021 showed an overall survival of 81%. Both CARTITUDE-1 and the phase 2 CARTITUDE-2 are ongoing. Cilta-cel was developed by Legend Biotech, and in December 2017, Janssen Biotech entered into a collaboration agreement with Legend Biotech to develop and commercialize cilta-cel. Multiple myeloma is a cancer that develops in white blood cells. In patients with multiple myeloma, cancer cells accumulate in the bone marrow, crowding out healthy cells. Most patients are diagnosed because of symptoms such as bone fracture or pain, low red blood cell counts, high calcium levels, kidney problems or infections. The American Cancer Society predicts almost 35,00 new cases of multiple myeloma will be diagnosed in 2021 and there will be more than 12,000 deaths this year.